MRK vs NRXS · P/E 33, rev $16.61B vs rev $3.6M
Merck & Company Inc (MRK) versus Neuraxis, Inc. (NRXS) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Neuraxis, Inc. (NRXS) is a biotechnology company listed on AMEX.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Latest reported NRXS revenue for 2025-12-31 was $3.6M. Net income was -$7.8M. Revenue was up 32.9% from 2024-12-31 to 2025-12-31. NRXS currently screens at market cap $83.1M.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. NRXS currently screens at market cap $83.1M.
Not investment advice. Open the MRK and NRXS stock pages for the full models.
Not investment advice.